Grace Halsey

A daily step count of as few as 3800 was associated with a 25% reduced risk of incident dementia in a cohort of 78 000 adults; the optimal count was fewer than 10 000.

Study participants who had HZ were at 30% greater sustained risk of stroke and CHD vs those who had not had HZ in this large multicohort prospective study.

Racial disparities in maternal, prenatal, and infant care are "stark and unacceptable," say authors of the March of Dimes 2022 Report Card.

One in 7 parents have not discussed vaccines with their child's primary clinician during the 2-year pandemic period, according to a CS Mott Children's Hospital poll.

Allopurinol exposures of 100 mg or more than 100 mg were associated with lower odds of first-ever ACS with some differences between sexes, a new study reports.

The analysis of a large biracial cohort found low levels of HDL-C linked to increased CHD risk in White but not Black adults and high HDL-C was not protective in either group.

Overall flu activity is at a 10-year high, according to the CDC's most recent influenza surveillance report, while US hospitals are already overwhelmed.

Teplizumab, an anti-CD3 monoclonal antibody, delayed the median onset of stage 3 T1D by approximately 2 years compared to placebo in a pivotal clinical trial.

Ordering an obesity phenotype should be as simple and routine as ordering an HbA1c or a lipid panel, says obesity expert Andres Acosta, MD, PhD.

The low rate of stroke prevention with oral anticoagulation in patients with atrial fibrillation is cause for significant concern, say investigators.

Obesity physician-scientist Andres Acosta, MD, PhD, reviews findings from recent studies he led that suggest true potential for phenotype-focused weight loss intervention.

While 60% of US psychologists have no openings for new patients, demand for treatment continues to rise, especially among adolescents and health care workers.

Bariatric surgery reduced by half the risk of CV events including myocardial infarction, heart failure, and stroke compared to nonsurgical care.

Obesity phenotyping uses a battery of validated tests and procedures to determine the root cause of a patient's disease and then match treatment accordingly.

A vaccine against fentanyl could stop the intense euphoria the drug creates and also block dangerous physiologic responses like respiratory depression, a new study suggests.

Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.

Pooled phase 3 data from LIBERTY-EoE-TREET presented at ACAAI 2022 reinforce May 2022 FDA approval of dupilumab for eosinophilic esophagitis.

Acosta, a pioneer in the phenotyping of obesity, says one-third of patients don't respond to treatment and he knows why.

Baxdrostat shows potential to represent the first new class of antihypertensive agents approved since 2017.

The Mass General Brigham clinical intervention and study included 10 000 participants and resulted in significant reductions in SBP/DBP and LDL-C.

Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.

Equifax, Experian, and TransUnion announced 3 major changes to medical debt reporting, expected to remove ~70% of medical collection debt tradelines from consumer credit reports.

AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.

The novel approach to targeted obesity treatment could improve weight loss outcomes, suggest findings from ObesityWeek® 2022.

Study authors saw a positive dose-response relationship driven by hemorrhagic stroke in young adults who were moderate-to-heavy drinkers in their 20s and 30s.

The Nerivio REM device demonstrated a statistically significant reduction in migraine days/month vs a placebo device in both chronic and episodic migraine.

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.

Apixaban was associated with up to a 28% lower risk of GI bleeding vs the 3 other direct oral anticoagulants in the first large-scale comparative analysis.